The group’s new platelet-rich plasma (PRP) offering meets international standards for compliance, safety, and efficacy
MIAMI LAKES, Florida—Adimarket, LLC, a subsidiary of the Global Stem Cells Group, today announced the availability of a new product that is a viable treatment option in a host of regenerative medicine sectors. With its new platelet-rich plasma (PRP) product, Adimarket will provide physicians with an exciting treatment protocol that can deliver relief to patients needing critical aesthetic, wound, and orthopedic care.
PRP is a super biological product of sorts, composed of a higher concentration of platelets than what is usually found in blood — 6-10 times more, on average. Adimarket’s PRP kit is the first of its kind in the stem cells and regenerative medicine industry, seeking to deliver higher platelet counts in an affordable and easy-to-use system. The revolutionary system is designed to shorten total processing time and reduce human error as it maximizes platelet concentration numbers. Adimarket’s offering has the capability of producing both leukocyte-rich and leukocyte-poor PRP and works in a variety of centrifuge systems.
PRP has been gaining interest and traction in the world of stem cell therapies and regenerative medicine. For clinicians working in the aesthetics, wound care, and orthopedic sectors, PRP has proven be a promising treatment option in offering relief to their patients.
In developing its PRP product, Adimarket researchers and scientists adhered to the highest international standards, making the product a viable option for physicians across the globe. With the launch of this new product, Adimarket is looking to expand its reach into new markets across the Middle East and Europe.
“Adimarket and its products have been met with great enthusiasm from physicians in the US and Latin America,” said Benito Novas, CEO of the Global Stem Cells Group. “With the launch of this new PRP product, our goal is to continue to serve our partners in those markets while expanding our presence into Europe and the Middle East. Our ultimate goal is to help more physicians across the globe deliver critical stem cell treatments to their patients, with the goal of alleviating unnecessary suffering.”
The keynote will highlight trends in social media marketing for physicians working in aesthetics
MIAMI LAKES, Florida—Benito Novas, CEO of Aesthetica Marketing Group (AMG), has been selected to serve as the keynote speaker at the upcoming Congreso del la Sociedad Chilena de Medicina y Estética. AMG, which is sponsoring the Chilean congress, is an American company focused on providing doctors working in the aesthetics medical industry practical solutions for their marketing challenges. The congress will be held on August 22-24, 2019 at the Hotel InterContinental Santiago in Santiago, Chile.
The annual event is the group’s main event, attracting physicians in the aesthetics medical industry across Chile and beyond. Novas’ keynote lecture will highlight current trends and best practices in social media and how physicians working in the aesthetics industry can better leverage social media in increasing the success of their practices.
During the congress, AMG will also launch two new courses focused on the aesthetics market, Pellet Therapy Certification and an IV/Chelation course.
The Pellet Therapy Certification course will provide practitioners with comprehensive clinical knowledge of this therapy option—one that is gaining rapid traction and recognition globally. Facilitators will present scientific reviews, case studies, and procedural training during the workshop. Attendees will be provided an in-depth introduction to pellet therapy, supported by reviews of clinical evidence on the need for customized dosing, in addition to assessing pellet dosing protocols for male and female patients. Pellet sterility, equipment, and what to look for in a compounding pharmacy will also be discussed.
AMG’s IV/Chelation course has been redesigned and now includes the most recent practices and protocols in intravenous nutritional therapies, in addition to chelation therapy in regard to its uses in lead toxicity and other heavy metals. Lecturers will not only cover the fundamentals of IV therapy and expand on the use of vitamins, minerals, amino acids, and other unique parenteral compounds but also review various aspects of integrating IV therapy into practice, as well as implementation strategies. Faculty presenters additionally will discuss potential application of the therapy in cancer treatment protocols, thus giving attendees the unique opportunity to learn about the most cutting-edge uses of IV therapy as a treatment method. At the conclusion of the course, clinicians will have a thorough understanding of how to perform IV therapy in both theory and practice.
To learn more about the upcoming Congreso del la Sociedad Chilena de Medicina y Estética or to register, visit https://sochimce.cl/congreso/. To learn more about Aesthetica Marketing Group, visit https://esteticamarketing.com/.
Adimarket, LLC Launches New Product for Physicians Seeking Regenerative Medicine and Stem Cell Centers
The comprehensive guide, “Proposal for Setting Up a Regenerative Medicine and Stem Cell Treatment Center” is available for purchase on Adimarket’s online store.
MIAMI LAKES, Florida—Adimarket, LLC, a subsidiary of the Global Stem Cells Group, has launched a new product for physicians interested in starting regenerative medicine and stem cell treatment centers. The guide, entitled “Proposal for Setting Up a Regenerative Medicine and Stem Cell Treatment Center” provides physicians with valuable information to guide them through the process of proposing and setting up new centers in the industry.
The comprehensive guide provides physicians with a one-stop place to find information critical to setting up a treatment center and includes information about training, equipment installation, cellular product storage procedures, supply inventories, laboratory startup, and more. The guide covers both scientific and administrative training concepts to help enable physicians to start their own centers at the lowest cost possible.
By following the guide, clinic officials will be able to launch a center with a wide range of cell lineages and products available, as well as have at its disposal the industry’s leading patient treatment protocols and standard operating procedures used by the Global Stem Cells Group’s global clinical network.
“For physicians looking to add regenerative medicine protocols to their current practices, Adimarket’s guide is a must-have resource,” said Benito Novas, CEO of the Global Stem Cells Group. “Our hope is that our guide will give more physicians the knowledge, tools, and confidence necessary to offer regenerative medicine and stem cell treatments to their patients to help alleviate suffering.”
To learn more about Adimarket and to purchase the “Proposal for Setting Up a Regenerative Medicine and Stem Cell Treatment Center,” visit https://www.adimarket.net/. To learn more about the Global Stem Cells Group, visit http://www.stemcellsgroup.com/.
The Global Stem Cells CEO will give two additional lectures on marketing and future outlooks for the stem cells industry as well as lead a magistral class for attendees
MIAMI LAKES, Florida—Benito Novas has been invited as a keynote speaker at an upcoming medical congress hosted by the Mexican Board of Aesthetic Gynecology. The group’s fourth congress, the 4to Congreso Internacional de Ginecología Lasar y Funcional, will be held on September 25-28, 2019 at the Holiday Inn hotel in Boca del Rio in Veracruz, Mexico.
Novas, is the Vice President of Public Relations of the International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine. In addition to his keynote speech, Novas will also lecture on two additional topics during the congress as well as lead a magistral class for conference attendees.
Benito Novas is a highly sought-after speaker in the world of stem cell advancements, having served as a successful business owner in the industry with his holding the Global Stem Cells Group. Thanks to Novas’ and his team’s efforts, access to regenerative medicine has expanded exponentially across the globe. Additionally, Novas is a well-regarded marketing professional who has created a successful marketing model for private medical organizations to expand and grow their industry recognition.
Congress attendees will have the opportunity to hear Novas’ talks on the current and future state of stem cells as well as the importance of digital marketing in the medical field. In his lecture on current and future outlooks for stem cells advancement, Novas will share information about current stem cells clinical trials and growing expectations in the industry as well as how FDA policies can influence markets not only in the US but also beyond.
In his lecture on digital marketing, Novas will address why doctors must utilize digital marketing strategies to grow a successful practice. He will look at current trends in how people meet each other and network in today’s increasingly digital world and how social medial plays a role in today’s networking. He will additionally provide strategic tips to attendees on how to capitalize on social media trends to grow practice influence. Some of the tools Novas will discuss include Google Ads and Facebook Ads, as well as what type of content to post to generate engagement with prospective customers and clients.
Novas will also conduct a magistral class following the congress for professionals interested in learning more about digital marketing. During the course, Novas will discuss how practitioners can implement the latest marketing techniques into their practices, including how to create a powerhouse digital marketing team by using platforms such as Fiverr, Upwork, and others.
To learn more about ISSCA’s Miami symposium or to register for the event, visit https://www.issca.us/.
ISSCA will partner with SIISDET at the October 2019 event, which will share valuable information with physicians regarding recent breakthroughs in regenerative medicine
MIAMI LAKES, Florida—The International Society for Stem Cells Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, will co-host a symposium in October 2019 with the Sociedad Internacional en Investigación, Salud, Desarrollo Empresarial (SIISDET). The event will be held at the University of Miami on October 22-24, 2019 in the West Ballroom of the Shalala Student Complex.
The Miami symposium will feature educational sessions and product information and demonstrations aimed at doctors looking to incorporate regenerative medicine into their practices. Industry experts will be on hand to share the latest information on the newest compounds in the allogeneic stem cells market, including exosomes, amniotic fluid compounds, and cord blood products.
Allogeneic compounds have gained growing popularity in regenerative medicine due to their increased safety and treatment efficacy. With this in mind, ISSCA representatives will be on hand to give physicians the opportunity to learn more about these popular treatment solutions and how they can be utilized in their practices.
“We are pleased to be able to partner with SIISDET to be able to offer this exciting symposium at the University of Miami,” said Benito Novas, CEO of ISSCA. “We are continually seeking ways to bring the latest advances in regenerative medicine to physicians across the globe. Our Miami symposium will play a critical role in accomplishing this by helping physicians expand their knowledge bases and explore new treatment options in regenerative medicine.”
In addition to educational sessions, the Miami symposium will provide networking and social opportunities for those in attendance. Events on the agenda include an optional boat trip around Miami on the Miami River and a Columbian Day celebration offering live music and Colombian cuisine to symposium attendees.
To learn more about ISSCA’s Miami symposium or to register for the event, visit https://www.issca.us/.
The innovative new center will provide training in regenerative medicine for doctors located in Belgium and France.
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has signed an agreement with Belgium’s Churchill Aesthetic Center. Beginning in July 2019, the center will offer stem cells certification programming for physicians in Belgium and France looking to add regenerative medicine treatment options to their practices.
ISSCA’s Belgian partnership builds on the group’s mission to reach new markets and expand regenerative medicine treatment options to physicians across the globe who want to offer new treatment options to their patients suffering from degenerative diseases and sports injuries. In its most recent clinic openings and partnerships, ISSCA has primarily focused on expanding efforts in the Middle East, US, and Latin America. The group recently set its sights on European expansion, with the partnership in Belgium serving as its second center in Europe, with the other located in Barcelona.
The cutting-edge facility will be equipped by Adimarket, LLC, a subsidiary of the Global Stem Cells Group. Adimarket will outfit the center with equipment and supplies designed to not only teach doctors about the latest protocols in regenerative medicine but also to treat patients suffering from degenerative diseases and sports injuries. Physicians training at the facility will have access to the proven expertise of ISSCA’s global network and training protocols.
“We look forward to ISSCA’s exciting new partnership with Belgium’s Churchill Aesthetic Center and the possibilities it brings in delivering safe and effective regenerative medicine treatment options to more patients across the globe,” said Benito Novas, CEO of the Global Stem Cells Group. “This partnership will help us prepare more physicians to deliver cutting edge treatment options to their patients that help alleviate suffering while also achieving our mission of expanding our global reach.”
Benito Novas, Global Stem Cells Group CEO Announces Opening of New Stem Cell Center in Valencia, Spain
The new center will continue the Global Stem Cells Group’s mission to expand access to stem cell therapies and training to physicians across the globe.
MIAMI LAKES, Florida—A new Stem Cell Center is set to open its doors in Spain. Benito Novas, CEO of the Global Stem Cells Group (GSCG), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has announced the opening of the group’s Valencia, Spain center. The new clinic will be the group’s third operation in Spain and the fourth in Europe.
The Global Stem Cells Group’s Valencia center joins the already existing centers in , which include locations in Bruselas, Madrid, and Barcelona. With the opening of the new center, the GSCG will boast 41 such locations across the globe.
Novas noted that the group has been focusing its efforts on opening its cutting-edge Stem Cell Centers in Europe, in part due to the group’s recognition that regenerative medicine is a fast-growing field across the continent.
“We are pleased to be able to open the doors on a new Stem Cells Center in Europe,” noted Novas. “The GSCG is continually exploring opportunities to deliver new stem-cell based treatment options to patients across Europe, and the Valencia center gives us the opportunity to do this while meeting our strategic mission to expand our presence in Europe.”
In opening the new center, the GSCG has signed an agreement with Dra. Laura Maria Caicedo, medical director of the Instituto Valenciano MEDEC (https://medec.es/conoce-medec/#equipoMedico). Dr. Caicedo is a specialist on hair loss with an interest in delivering stem cell based treatments to her patients and others in Valencia.
“I am thrilled to lead the efforts at the Stem Cell Center in Valencia,” said Dra. Caicedo. “I am looking forward to utilizing cutting-edge therapy options based in stem cell science to help treat patients suffering from hair loss. Additionally, the opportunity is an exciting one given the Global Stem Cells Group’s excellent reputation and stature as the longest-standing and most respected stem cells network. I’m looking forward to learning from other physicians in the network across the globe and sharing my expertise with other practitioners in regenerative medicine.”
The GSCG will provide the Valencia center with the newest and most effective marketing tools in the field to help the franchise increase its performance in recruiting new patients.
Marketing support is one of the many benefits of joining the GSCG’s expanding global network of clinics. Being part of the group’s network gives physicians access to other experts within the its global network, add to their practice the newest regenerative medicine protocols, and have access to a proven marketing strategy developed by GSCG.
To learn more about the Global Stem Cells Group, visit http://www.stemcellsgroup.com/.
The global group will hold its 6th International Regenerative Medicine Symposium in October 2019.
MIAMI LAKES, Florida—The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has announced its 6th annual International Regenerative Medicine Symposium in Buenos Aires. The event will attract physicians from across the globe and will be held on October 12, 2019 in Buenos Aires, Argentina at the Hotel Panamericano.
The past five years of the ISSCA sponsored event have been a global success. This year’s meeting will feature educational sessions and product information and demonstrations, with a special focused placed on the newest compounds in the allogeneic stem cells market, including exosomes, amniotic fluid compounds, and cord blood products. With allogeneic compounds growing in popularity, safety, and treatment efficacy, ISSCA will give physicians the opportunity to learn more about them and how they can be incorporated into their practices.
A number of experts within the field of regenerative medicine are confirmed for the event and include.
• Dra. Maritza Novas, Chief of I&D, Global Stem Cells Group USA
• Dr. Leopoldo Paradas, President of Asociación Chilena de Ingeniería Tisular
• Dr. Matias Fernandez Vina Argentinian Cardiologist
“We are pleased to be hosting our popular International Regenerative Medicine Symposium for a sixth year,” said Benito Novas, CEO of ISSCA. “Each year our symposium focuses on critical topics and exciting breakthroughs in the field of regenerative medicine, and this year is no different as we seek to retain our position as a vanguard in the field.”
Physicians interested in registering for or learning more about the Buenos Aires symposium may visit https://www.issca.us/.
The newly developed program gives physicians the opportunity to learn the latest methods and knowledge in the field of regenerative medicine.
MIAMI LAKES, Florida—The International Society for Stem Cells Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has announced a new course for physicians interested in gaining certification in regenerative medicine. The course was developed out of the group’s highly successful global conference certifications, providing physicians a newly designed and more intimate and personalized smaller group training through which to gain critical skills and knowledge in the field of regenerative medicine.
Through completion of the certification course, physicians will learn how they can add cell-based product protocols to their existing medical practices, including those using exosomes, amniotic fluid, and cord blood.
A host of global experts practicing within the field will be on hand to lead attendees through the new training. They will share first-hand scientific information on the science behind cell therapies and cell-based products and their clinical applications. In-depth examination of clinical trials that demonstrate the safety and efficacy of cell-based products will also be part of the one-day training.
Physicians attending the certification will also learn how to distinguish between the most popular cellular products on the market and what factors to keep in mind when choosing stem cell protocols as a therapeutic alternative. Course faculty will additionally lead attendees through how to structure treatment plans and protocols for patients who may benefit from stem cell therapies.
“We are pleased to be able to offer this exciting and informative new training to physicians interested in adding stem cell treatment options to their current medical practices,” said Benito Novas, CEO of ISSCA. “We seek to remain at the forefront of the stem cells field by continuously innovating and offering the global community the training they need to deliver effective, cutting edge treatment options to their patients. We decided to offer this new training in part due to the demand for it from our customers, who are eager to expand their knowledge base and offer new treatment options to their patients.”
ISSCA has set four dates and locations for its new certification course, and this is the first time such certification has been held by the group outside of the United States:
• Santiago de Chile, Chile: September 5, 2019
• Bogota, Colombia: October 4, 2019
• Buenos Aires, Argentina: October 11, 2019
• Miami, Florida (in English): November 1, 2019
To learn more about ISSCA’s latest certification program and to register, or to learn more about ISSCA, visit https://www.issca.us/.
CES University of Medellín, Colombia bestowed the honor upon Novas due to his exemplary work in marketing and the regenerative medicine field
MIAMI LAKES, Florida—Benito Novas, Vice President of The International Society for Stem Cell Application (ISSCA), a multi-disciplinary community of scientists and physicians collaborating to treat diseases and lessen human suffering through science, technology, and regenerative medicine, has been awarded the degree of Dr. Honoris Causa from CES University in Medellín. The award comes in recognition of his work as a global leader in marketing and as a key figure in the regenerative medicine field.
For the past 15 years, Novas has worked as a marketing professional and is a recognized leader in the industry. Novas created a specific marketing model that has proven to be successful for private medical institutions to gain industry recognition and grow into thriving organizations. He is a sought-after speaker and has been an invited guest and keynote speaker at a number of medical congresses across the globe, sharing his latest marketing strategies with medical institutions looking to recruit new patients.
Novas has also played an integral role in the regenerative medicine field as a business owner. His contributions to the field are noteworthy and include organizing various congresses and certification courses across five continents. His holding, the Global Stem Cells Group, has worked to increase access to affordable equipment and regenerative medicine supplies to doctors across the world. His foundation has provided hundreds of free regenerative medicine treatments in each country where he has visited.
“It is an honor to have such a prestigious award bestowed upon me” said Novas. “I am grateful to the administration at CES University for considering me for this award.”